Does aging reduce virus-specific T-cell surveillance and raise shingles risk?

Herpes zoster reflects reactivation of varicella-zoster virus (VZV), which persists latently in sensory ganglia after primary infection. In older adults, declining VZV-specific cellular immunity provides a well-supported explanation for rising reactivation risk.

Clinical and epidemiologic evidence

• Aging is strongly associated with higher herpes zoster risk; incidence rises sharply after age 50. A meta-analysis found older age associated with increased zoster risk (RR 1.65, 95% CI 1.37–1.97), although estimates varied across studies.
• In the prospective SHEZ cohort of adults aged ≥50 years, herpes zoster incidence was 10.9 per 1,000 person-years. Weaker VZV skin-test responses were associated with greater zoster incidence and severity.
• VZV-specific cellular responses decline with age: one older-adult cohort estimated a 2.7%–3.9% annual reduction depending on assay, while studies found lower IFN-γ ELISPOT responses and fewer circulating VZV-specific IFN-γ-secreting CD4 T cells in older adults. Antibody levels did not show a comparable age-related decline.

Mechanistic interpretation

• VZV-specific T-cell immunity helps maintain latency and suppress viral replication in sensory ganglia. Age-related reduction in this surveillance plausibly permits intermittent viral activity and, in some cases, clinical reactivation.
• A prospective study in adults aged 40–80 found increasing blood-cell VZV DNA burden from about age 50 alongside declining cellular responses. This is consistent with diminished viral control, but blood-cell DNA is an unvalidated marker of subclinical reactivation rather than an individual predictor of shingles.

Clinical implications

• For a 71-year-old, the age-related increase in zoster susceptibility is clinically meaningful. Peripheral-blood immune tests do not reliably quantify ganglionic protection, and no validated T-cell threshold predicts an individual’s risk.

Bottom line

• The claim is supported: aging reduces VZV-specific T-cell surveillance, weakening maintenance of latency and contributing to the substantially higher risk of herpes zoster reactivation in later life.